World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
39458
World Ranking
10747
National Ranking
5525

Xiaowei Xu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Xiaowei Xu sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 336 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Xiaowei Xu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Xiaowei Xu sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Xiaowei Xu is affiliated with the University of Pennsylvania in the United States. Their research primarily spans the fields of medicine, biochemistry, genetics and molecular biology, and immunology and microbiology. Within these domains, Xiaowei Xu has contributed extensively to oncology, immunology, molecular biology, cell biology, and hematology.

The scientist's work focuses on several key topics including cancer immunotherapy and biomarkers, immunotherapy and immune responses, CAR-T cell therapy research, cutaneous melanoma detection and management, immune cell function and interaction, melanoma and MAPK pathways, and hematopoietic stem cell transplantation.

Frequent co-authors collaborating with Xiaowei Xu include Giorgos C. Karakousis, Tara C. Mitchell, Ravi K. Amaravadi, Lynn M. Schuchter, and Alexander C. Huang.

Publications by Xiaowei Xu appear regularly in several prominent scientific journals. The most frequent publication venues are Nature Communications and Cancer Research with six publications each, followed by Journal of Clinical Oncology and Annals of Surgical Oncology with five publications each, and Cell Reports with four publications.

Some recent papers authored or co-authored by Xiaowei Xu include:

  • Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms, 2020, Immunity
  • Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC), 2021, Nature Medicine
  • ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis, 2020, Cancer Cell
  • Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics, 2022, Nature Immunology
  • Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy, 2021, Nature Communications

Best Publications

  • Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response

    Gang Chen;Alexander C. Huang;Wei Zhang;Wei Zhang;Gao Zhang

  • Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

    Christina Twyman-Saint Victor;Andrew J. Rech;Amit Maity;Ramesh Rengan;Ramesh Rengan

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

    Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

  • A tumorigenic subpopulation with stem cell properties in melanomas.

    Dong Fang;Thiennga K. Nguyen;Kim Leishear;Rena Finko

  • T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

    Alexander C. Huang;Michael A. Postow;Michael A. Postow;Robert J. Orlowski;Rosemarie Mick

  • TOX transcriptionally and epigenetically programs CD8 + T cell exhaustion

    Omar Khan;Josephine R. Giles;Sierra McDonald;Sasikanth Manne

  • Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

    Jessie Villanueva;Adina Vultur;John T. Lee;Rajasekharan Somasundaram

  • Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

    Jean-Christophe Beltra;Sasikanth Manne;Mohamed S. Abdel-Hakeem;Makoto Kurachi

  • Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification

    Jun Guo;Lu Si;Yan Kong;Keith T. Flaherty

  • Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients

    Thomas Condamine;George A. Dominguez;Je-In Youn;Andrew V. Kossenkov

  • Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors

    Vinit Kumar;Laxminarasimha Donthireddy;Douglas Marvel;Thomas Condamine

  • Enhancing CD8 + T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.

    Ying Zhang;Ying Zhang;Raj Kurupati;Ling Liu;Xiang Yang Zhou

  • A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

    Alexander C. Huang;Robert J. Orlowski;Robert J. Orlowski;Xiaowei Xu;Rosemarie Mick

  • Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

    Xiao Hong Ma;Sheng Fu Piao;Souvik Dey;Quentin McAfee

  • Isolation of a Novel Population of Multipotent Adult Stem Cells from Human Hair Follicles

    Hong Yu;Dong Fang;Suresh M. Kumar;Ling Li

  • sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

    Amanpreet Kaur;Amanpreet Kaur;Marie R. Webster;Katie Marchbank;Reeti Behera

  • Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation

    Suresh M. Kumar;Shujing Liu;Hezhe Lu;Hongtao Zhang

  • CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation

    Vinit Kumar;Pingyan Cheng;Thomas Condamine;Sridevi Mony

  • Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility

    Amanpreet Kaur;Amanpreet Kaur;Amanpreet Kaur;Brett L. Ecker;Stephen M. Douglass;Curtis H. Kugel

  • Evaluation of AJCC Tumor Staging for Cutaneous Squamous Cell Carcinoma and a Proposed Alternative Tumor Staging System

    Anokhi Jambusaria-Pahlajani;Peter A. Kanetsky;Pritesh S. Karia;Wei Ting Hwang

Frequent Co-Authors

Lynn M. Schuchter
Lynn M. Schuchter University of Pennsylvania
David E. Elder
David E. Elder Hospital of the University of Pennsylvania
Ravi K. Amaravadi
Ravi K. Amaravadi University of Pennsylvania
Meenhard Herlyn
Meenhard Herlyn The Wistar Institute
Phyllis A. Gimotty
Phyllis A. Gimotty University of Pennsylvania
Keith T. Flaherty
Keith T. Flaherty Harvard University
Ashani T. Weeraratna
Ashani T. Weeraratna Johns Hopkins University
Katherine L. Nathanson
Katherine L. Nathanson University of Pennsylvania
Wei Xu
Wei Xu Shenzhen University
David W. Speicher
David W. Speicher The Wistar Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The field of medicine in the USA offers many alternative educational routes and career options beyond the traditional MD. For those seeking clinical leadership positions, there are cheap DNP online programs that provide advanced nursing practice and administrative training without breaking the bank.

Students interested in pharmaceuticals can explore online pharmacy programs, which combine flexibility with a comprehensive curriculum for aspiring pharmacists.

For those drawn to the administrative and data management side of healthcare, pursuing RHIA certification programs online can open doors to in-demand roles in health information management.

Additionally, individuals seeking fast entry into the healthcare workforce may consider affordable medical billing and coding programs to gain vital skills for supporting patient care behind the scenes.

These diverse, flexible online programs make it possible to build a rewarding healthcare career, even for those balancing work or family commitments.

Best Scientists Citing Xiaowei Xu

Trending Scientists

Recently Published Articles